Janice K. Albrecht

35.1k citations

117 papers · 26.0k indexed · 15 hit papers · h-index 48

Hepatology top 0.01%
- Hepatitis C virus research 85
Epidemiology top 0.01%
- Liver Disease Diagnosis and Treatment 53
- Hepatitis B Virus Studies 38
- Respiratory viral infections research 9
Rheumatology top 0.2%
- Systemic Lupus Erythematosus Research 20
Infectious Diseases top 0.2%
- HIV/AIDS drug development and treatment 12
Virology top 2%
Genetics
- Chronic Lymphocytic Leukemia Research 18
Immunology
- Immunodeficiency and Autoimmune Disorders 8

Co-authors: John G. McHutchison Zachary Goodman Stuart C. Gordon Mitchell L. Shiffman Michael P. Manns Vinod K. Rustgi Thierry Poynard Kenneth Koury
Cited by: Hepatology Epidemiology Rheumatology
Partner nations: United States France Germany

In The Last Decade

Janice K. Albrecht

113 papers receiving 25.0k citations

Hit Papers

15 papers align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2011 Boceprevir for Untreated Chronic HCV Genotype 1 Infection
2011 Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
2010 Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial
2009 Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection
2003 Early Virologic Response to Treatment With Peginterferon Alfa–2B Plus Ribavirin in Patients With Chronic Hepatitis C
2002 Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C
2002 Adherence to combination therapy enhances sustained response in genotype-1–infected patients with chronic hepatitis C
2001 Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
2001 A Randomized, Double–Blind Trial Comparing Pegylated Interferon Alfa–2B to Interferon Alfa–2B As Initial Treatment for Chronic Hepatitis C
2001 Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C
1998 Interferon Alfa-2b Alone or in Combination with Ribavirin for the Treatment of Relapse of Chronic Hepatitis C
1998 Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C
1998 Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
1990 A Randomized, Controlled Trial of Interferon Alfa-2b Alone and after Prednisone Withdrawal for the Treatment of Chronic Hepatitis B
1989 Treatment of Chronic Hepatitis C with Recombinant Interferon Alfa

Peers

Countries citing papers authored by Janice K. Albrecht

Since Specialization

Citations

This map shows the geographic impact of Janice K. Albrecht's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Janice K. Albrecht with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Janice K. Albrecht more than expected).

Fields of papers citing papers by Janice K. Albrecht

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Janice K. Albrecht. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Janice K. Albrecht. The network helps show where Janice K. Albrecht may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Janice K. Albrecht, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Janice K. Albrecht Line = papers co-authored together Janice K. Albrecht links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa‐2b/ribavirin Stuart C. Gordon,Eric M. Yoshida,Eric Lawitz,Bruce R. Bacon,Mark Sulkowski,Mitchell Davis,Fred Poordad,J.‐P. Bronowicki,Rafael Esteban,Vilma Sniukiene,Margaret Burroughs,Weiping Deng,Frank J. Dutko,Clifford A. Brass,Janice K. Albrecht,K. Rajender Reddy	2013	17
2	Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies Richard J. O. Barnard,John A. Howe,Robert A. Ogert,Stefan Zeuzem,Fred Poordad,Stuart C. Gordon,Robert Ralston,Xiao Tong,Vilma Sniukiene,Julie Strizki,Desmon̄d Ryan,Jianmin Long,Ping Qiu,Clifford A. Brass,Janice K. Albrecht,Margaret Burroughs,Scott Vuocolo,Daria J. Hazuda	2013	54
3	Efficacy and safety of boceprevir plus peginterferon–ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis Savino Bruno,John M. Vierling,Rafael Esteban,Lisa M. Nyberg,Hugo Tanno,Zachary Goodman,Fred Poordad,Bruce R. Bacon,Keith Gottesdiener,Lisa D. Pedicone,Janice K. Albrecht,Clifford A. Brass,Seth Thompson,Margaret Burroughs	2012	40
4	Factors That Predict Response of Patients With Hepatitis C Virus Infection to Boceprevir Fred Poordad,Jean–Pierre Bronowicki,Stuart C. Gordon,Stefan Zeuzem,Ira M. Jacobson,Mark Sulkowski,Thierry Poynard,Timothy R. Morgan,Cliona Molony,Lisa D. Pedicone,Heather L. Sings,Margaret Burroughs,Vilma Sniukiene,Navdeep Boparai,Venkata Sasikiran Goteti,Clifford A. Brass,Janice K. Albrecht,Bruce R. Bacon	2012	150
5	484 PREDICTORS OF SUSTAINED VIROLOGIC RESPONSE AMONG GENOTYPE 1 PREVIOUS NON-RESPONDERS AND RELAPSERS TO PEGINTERFERON/RIBAVIRIN WHEN RE-TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN Stefan Zeuzem,John M. Vierling,Rafael Esteban,Alexandra L. Gibas,Stanislas Pol,Navdeep Boparai,Margaret Burroughs,Clifford A. Brass,Janice K. Albrecht,F. Poordad	2011	30
6	PREDICTORS OF CONSENT TO PHARMACOGENOMICS TESTING IN THE IDEAL STUDY Alison Jazwinski,Paul J. Clark,Alexander Thompson,Stuart C. Gordon,Eric Lawitz,Jonathan McCone,Stephanie Noviello,Clifford A. Brass,Lisa D. Pedicone,Janice K. Albrecht,Mark S. Sulkowski,Andrew J. Muir	2011	0
7	PREDICTING PEGINTERFERON-alpha AND RIBAVIRIN TREATMENT RESPONSE IN GENOTYPE 1 HCV PATIENTS - SIMPLE NOMOGRAMS TO SUPPORT CLINICIANS Alexander Thompson,Paul J. Clark,David M. Vock,Ruth M. Pfeiffer,Hans L. Tillmann,Keyur Patel,Susanna Naggie,Fred Poordad,Lisa M. Nyberg,Stephanie Noviello,Lisa D. Pedicone,Clifford A. Brass,Janice K. Albrecht,David B. Goldstein,John G. McHutchison,Thomas R. OʼBrien,Mark Sulkowski,Andrew J. Muir	2011	1
8	Boceprevir for Previously Treated Chronic HCV Genotype 1 Infectionbreakdown → Bruce R. Bacon,Stuart C. Gordon,Eric Lawitz,Patrick Marcellin,John M. Vierling,Stefan Zeuzem,Fred Poordad,Zachary Goodman,Heather L. Sings,Navdeep Boparai,Margaret Burroughs,Clifford A. Brass,Janice K. Albrecht,Rafael Esteban	2011	1229
9	Association of a polymorphism in the indoleamine- 2,3-dioxygenase gene and interferon-α-induced depression in patients with chronic hepatitis C Alicia K. Smith,Jason S. Simon,Eric L. Gustafson,Stephanie Noviello,J.F. Cubells,Michael P. Epstein,D.J. Devlin,Ping Qiu,Janice K. Albrecht,Clifford A. Brass,Mark Sulkowski,John McHutchinson,Andrew H. Miller	2011	69
10	Racial differences in hepatitis C treatment eligibility Michael T. Melia,Andrew J. Muir,Jonathan McCone,Mitchell L. Shiffman,John W. King,Steven K. Herrine,Greg Galler,Joseph R. Bloomer,Frederick A. Nunes,Kimberly Brown,Kevin D. Mullen,Natarajan Ravendhran,Reem Ghalib,Navdeep Boparai,Ruiyun Jiang,Stephanie Noviello,Clifford A. Brass,Janice K. Albrecht,John G. McHutchison,Mark Sulkowski	2011	36
11	Early Virologic Response to Treatment With Peginterferon Alfa–2B Plus Ribavirin in Patients With Chronic Hepatitis Cbreakdown → Gary L. Davis,John B. Wong,John G. McHutchison,Michael P. Manns,Joann Harvey,Janice K. Albrecht	2003	625
12	A Randomized, Double–Blind Trial Comparing Pegylated Interferon Alfa–2B to Interferon Alfa–2B As Initial Treatment for Chronic Hepatitis Cbreakdown → Karen L. Lindsay,Christian Trépo,Tobias Heintges,Mitchell L. Shiffman,Stuart C. Gordon,John C. Hoefs,Eugene R. Schiff,Zachary Goodman,Mark Laughlin,Ruji Yao,Janice K. Albrecht	2001	507
13	Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialbreakdown → Michael P. Manns,John G. McHutchison,Stuart C. Gordon,Vinod K. Rustgi,Mitchell L. Shiffman,Robert Reindollar,Zachary Goodman,Kenneth Koury,Mei–Hsiu Ling,Janice K. Albrecht	2001	4843
14	Is an “à la carte” combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? Thierry Poynard,John G. McHutchison,Zachary Goodman,Mei-Hsiu Ling,Janice K. Albrecht	2000	297
15	TT virus infection in patients with chronic hepatitis C virus infection - effect of primers, prevalence, and clinical significance M Mizokami,Janice K. Albrecht,Takanobu Kato,Etsuro Orito,Vicky C.H Lai,Zachary Goodman,Zhi Hong,Johnson Y.N. Lau	2000	22
16	Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis c John B. Wong,Thierry Poynard,Mei–Hsiu Ling,Janice K. Albrecht,Stephen G. Pauker,(unknown)	2000	68
17	Interferon Alfa-2b Alone or in Combination with Ribavirin for the Treatment of Relapse of Chronic Hepatitis Cbreakdown → Gary L. Davis,Rafael Esteban,Vinod K. Rustgi,John C. Hoefs,Stuart C. Gordon,Christian Trépo,Mitchell L. Shiffman,Stefan Zeuzem,Antonio Craxı̀,Mei-Hsiu Ling,Janice K. Albrecht	1998	1070
18	Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis Cbreakdown → John G. McHutchison,Stuart C. Gordon,Eugene R. Schiff,Mitchell L. Shiffman,William M. Lee,Vinod K. Rustgi,Zachary Goodman,Mei–Hsiu Ling,Susannah Cort,Janice K. Albrecht	1998	2818
19	Treatment of chronic hepatitis C with recombinant α-interferon. A multicentre randomized, controlled trial Gary L. Davis,L. Balart,Eugene R. Schiff,Karen L. Lindsay,Henry C. Bodenheimer,Robert P. Perrillo,William D. Carey,Ira M. Jacobson,John A. Payne,Jules L. Dienstag,David H. Van Thiel,Carlo H. Tamburro,Jay H. Lefkowitch,Janice K. Albrecht,Carlton Meschievitz,Terryl J. Ortego,Alexandra L. Gibas	1990	16
20	A Randomized, Controlled Trial of Interferon Alfa-2b Alone and after Prednisone Withdrawal for the Treatment of Chronic Hepatitis Bbreakdown → Robert P. Perrillo,E. Schiff,Gerald L. Davis,Henry C. Bodenheimer,Karen L. Lindsay,John A. Payne,Jules L. Dienstag,C. O’Brien,Carlo H. Tamburro,Ira M. Jacobson,Richard E. Sampliner,David Feit,Jay H. Lefkowitch,Mary C. Kuhns,Carlton Meschievitz,Bharati Sanghvi,Janice K. Albrecht,Alexandra L. Gibas	1990	664

About Janice K. Albrecht

Janice K. Albrecht is a scholar working on Hepatology, Epidemiology and Genetics, having authored 117 papers that have together received 26.0k indexed citations. Recurring topics across this work include Hepatitis C virus research (85 papers), Liver Disease Diagnosis and Treatment (53 papers), Hepatitis B Virus Studies (38 papers), Systemic Lupus Erythematosus Research (20 papers), Chronic Lymphocytic Leukemia Research (18 papers), HIV/AIDS drug development and treatment (12 papers), Respiratory viral infections research (9 papers) and Immunodeficiency and Autoimmune Disorders (8 papers). The work is most often cited by research in Hepatology (23.6k citations), Epidemiology (21.7k citations) and Rheumatology (2.5k citations). Janice K. Albrecht has collaborated with scholars based in United States, France and Germany. Frequent co-authors include John G. McHutchison, Zachary Goodman, Stuart C. Gordon, Mitchell L. Shiffman, Michael P. Manns, Vinod K. Rustgi, Thierry Poynard, Kenneth Koury, Eugene R. Schiff and Robert Reindollar.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact